Trendelenburg position for acute anterior circulation ischaemic stroke with large artery atherosclerosis aetiology (HOPES 3): rationale and design.

IF 2.6 1区 医学
Xiaoqiu Li, Zhenni Guo, Lu Wang, Yue Wang, Thanh Nguyen, Yi Yang, Hui-Sheng Chen
{"title":"Trendelenburg position for acute anterior circulation ischaemic stroke with large artery atherosclerosis aetiology (HOPES 3): rationale and design.","authors":"Xiaoqiu Li, Zhenni Guo, Lu Wang, Yue Wang, Thanh Nguyen, Yi Yang, Hui-Sheng Chen","doi":"10.1136/svn-2023-002868","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>The effect of the head position as a non-pharmacological therapy on acute ischaemic stroke (AIS) remains inconclusive. Our recent Head dOwn-Position for acutE moderate ischaemic Stroke with large artery atherosclerosis (HOPES 2) suggested the safety, feasibility and potential benefit of the head-down position (HDP) in AIS.</p><p><strong>Aim: </strong>To investigate the benefit of HDP in acute moderate ischaemic stroke patients with large artery atherosclerosis (LAA).</p><p><strong>Sample size estimates: </strong>Based on a two-sided 0.05 level of significance, 600 patients are expected to yield the superiority hypothesis with 80% power, stratified by age, sex, history of diabetes, baseline systolic blood pressure, location of index vessel, National Institutes of Health Stroke Scale Score at randomisation, onset to randomisation time, progression to moderate neurological deficit due to early neurological deterioration and degree of responsible vessel stenosis.</p><p><strong>Design: </strong>Head dOwn-Position for acutE moderate ischaemic Stroke with large artery atherosclerosis(HOPES 3) is a prospective, randomised, open-label, blinded endpoint and multicentre study. Eligible patients who had an ischaemic stroke will be randomly assigned (1:1) into the HDP group receiving -20° Trendelenburg plus standard medical care in compliance with national guidelines, or control group only receiving standard medical care in compliance with national guidelines.</p><p><strong>Outcome: </strong>The primary outcome is favourable functional outcome, defined as modified Rankin Scale 0-2 at 90 days. Safety outcomes are HDP-related adverse events. All outcomes will have blinded assessment and will be analysed on the intention-to-treat basis.</p><p><strong>Conclusions: </strong>The results of HOPES 3 will provide evidence for the effect of HDP in acute moderate ischaemic stroke patients with LAA within 24 hours of onset or in patients with progression from mild neurological deficit within 24 hours.</p><p><strong>Trial registration number: </strong>NCT06010641.</p>","PeriodicalId":48733,"journal":{"name":"Journal of Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/svn-2023-002868","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: The effect of the head position as a non-pharmacological therapy on acute ischaemic stroke (AIS) remains inconclusive. Our recent Head dOwn-Position for acutE moderate ischaemic Stroke with large artery atherosclerosis (HOPES 2) suggested the safety, feasibility and potential benefit of the head-down position (HDP) in AIS.

Aim: To investigate the benefit of HDP in acute moderate ischaemic stroke patients with large artery atherosclerosis (LAA).

Sample size estimates: Based on a two-sided 0.05 level of significance, 600 patients are expected to yield the superiority hypothesis with 80% power, stratified by age, sex, history of diabetes, baseline systolic blood pressure, location of index vessel, National Institutes of Health Stroke Scale Score at randomisation, onset to randomisation time, progression to moderate neurological deficit due to early neurological deterioration and degree of responsible vessel stenosis.

Design: Head dOwn-Position for acutE moderate ischaemic Stroke with large artery atherosclerosis(HOPES 3) is a prospective, randomised, open-label, blinded endpoint and multicentre study. Eligible patients who had an ischaemic stroke will be randomly assigned (1:1) into the HDP group receiving -20° Trendelenburg plus standard medical care in compliance with national guidelines, or control group only receiving standard medical care in compliance with national guidelines.

Outcome: The primary outcome is favourable functional outcome, defined as modified Rankin Scale 0-2 at 90 days. Safety outcomes are HDP-related adverse events. All outcomes will have blinded assessment and will be analysed on the intention-to-treat basis.

Conclusions: The results of HOPES 3 will provide evidence for the effect of HDP in acute moderate ischaemic stroke patients with LAA within 24 hours of onset or in patients with progression from mild neurological deficit within 24 hours.

Trial registration number: NCT06010641.

治疗大动脉粥样硬化性急性前循环缺血性脑卒中的 Trendelenburg 体位(HOPES 3):原理与设计。
理由:头低位作为一种非药物疗法对急性缺血性中风(AIS)的治疗效果仍无定论。我们最近针对伴有大动脉粥样硬化的急性中度缺血性卒中(HOPES 2)进行的头低位(HDP)研究表明,头低位(HDP)对急性中度缺血性卒中具有安全性、可行性和潜在益处:根据双侧 0.05 的显著性水平,按年龄、性别、糖尿病史、基线收缩压、指数血管位置、随机化时美国国立卫生研究院卒中量表评分、发病至随机化时间、早期神经功能恶化导致的中度神经功能缺损进展以及责任血管狭窄程度进行分层,预计 600 名患者可提出 80% 的优势假设:头部自主定位治疗大动脉粥样硬化中度缺血性脑卒中(HOPES 3)是一项前瞻性、随机、开放标签、终点盲法多中心研究。符合条件的缺血性中风患者将被随机分配(1:1)到HDP组,接受-20° Trendelenburg加符合国家指南的标准医疗护理,或对照组仅接受符合国家指南的标准医疗护理:主要结果是良好的功能结果,定义为 90 天后修改后的 Rankin 量表 0-2。安全性结果为与 HDP 相关的不良事件。所有结果都将进行盲法评估,并在意向治疗基础上进行分析:HOPES 3的结果将为HDP对急性中度缺血性卒中患者在发病24小时内出现LAA或在24小时内轻度神经功能缺损进展的效果提供证据:试验注册号:NCT06010641。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Investigative Medicine
Journal of Investigative Medicine MEDICINE, GENERAL & INTERNALMEDICINE, RESE-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
111
期刊介绍: Journal of Investigative Medicine (JIM) is the official publication of the American Federation for Medical Research. The journal is peer-reviewed and publishes high-quality original articles and reviews in the areas of basic, clinical, and translational medical research. JIM publishes on all topics and specialty areas that are critical to the conduct of the entire spectrum of biomedical research: from the translation of clinical observations at the bedside, to basic and animal research to clinical research and the implementation of innovative medical care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信